TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04281030

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PMR (Progressive muscle relaxation therapy)
Description: Technique for learning to monitor and control the state of muscular tension. The relaxation therapy should take about 20 minutes a day.
Study: NCT04128930

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PAP titration at home
Description: Fixed CPAP or APAP titration at home

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAP titration at home
Description: Fixed CPAP or APAP titration at home
Study: NCT02389179

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: The drug/dosage of Vitamin D3 will be given monthly or bi-weekly depending on the type of arm that the subjects are randomised into under direct supervision.
Study: NCT04281030

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monitored Usual Care (MUC)
Description: Subjects will be given basic migraine information such as evidence-based ways to treat migraine: treat early, limit acute medications \< 2-3 days/week, and call the primary care physician (PCP) if abortive medications are used more frequently.
Study: NCT02163525

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Global Fibroid Ablation (GFA)
Description: GFA is radiofrequency ablation of fibroids. This is a laparoscopic procedure whereby a radiofrequency probe is inserted into the fibroid under laparoscopic and ultrasound guidance. Each fibroid is heated to temperatures averaging 95 deg C. The fibroid undergoes coagulative necrosis and shrinks and/or disappears.
Study: NCT02389179

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: The drug/dosage of Vitamin D3 will be given monthly or bi-weekly depending on the type of arm that the subjects are randomised into under direct supervision.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: The drug/dosage of Vitamin D3 will be given monthly or bi-weekly depending on the type of arm that the subjects are randomised into under direct supervision.
Study: NCT04654793

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot assisted inclined bed treatment and FES
Description: FES was performed at the same time as the robot-assisted inclined bed treatment once a day for 30 minutes, 5 days a week for 4 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional inclined bed treatment
Description: conventional inclined bed treatment for 30 minutes once a day for 4 weeks, 5 days a week
Study: NCT00503698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: 20 mcg/kg/day, injected s.c. (under the skin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo injected s.c (under the skin)
Study: NCT00153179

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acipimox
Description: subjects will receive acipimox 250 mg orally every 6 hours (or matching placebo) for 7 days, including a dose at 6am on the morning of the study testing visit
Study: NCT04055779

Intervention type: OTHER
Intervention: estimation method for arterial occlusion pressure
Description: The patients will receive induced hypotensive anaesthesia and the tourniquet pressure will be based on the AOP.the tourniquet pressure will be determined based on the AOP which will be determined by the estimation formula (AOP=\[SBP+10\]/KTP) . The calculation is based on using initial SBP and tissue padding coefficient values , according to limb circumferences of the patient.After calculation of AOP, tourniquet pressures will be determined by adding a safety margin of 20 mmHg to AOP values(tourniquet pressure=AOP+20 mmHg).

Intervention type: OTHER
Intervention: estimation method for arterial occlusion pressure
Description: The patients will receive induced hypotensive anaesthesia and the tourniquet pressure will be based on the AOP.the tourniquet pressure will be determined based on the AOP which will be determined by the estimation formula (AOP=\[SBP+10\]/KTP) . The calculation is based on using initial SBP and tissue padding coefficient values , according to limb circumferences of the patient.After calculation of AOP, tourniquet pressures will be determined by adding a safety margin of 20 mmHg to AOP values(tourniquet pressure=AOP+20 mmHg).

Intervention type: OTHER
Intervention: the limb occlusion pressure
Description: : using the ultrasound Doppler technique and the tourniquet will be inflated until the arterial pulsations disappear at the side of the operation. This pressure will be recorded as LOP.using the ultrasound Doppler technique and the tourniquet will be inflated until the arterial pulsations disappear at the side of the operation. This pressure will be recorded as LOP .the tourniquet cuff will be inflated to the pressure according to theguidelines of the Association of Perioperative Registered Nurses(AORN) which recommends that a safety margin of 40 mmHg should be added for AOP below 130 mmHg, 60 mmHg for AOP between 131 mmHg and 190 mmHg, and 80 mmHg for AOP above 190 mmHg for adult patients

Intervention type: OTHER
Intervention: the limb occlusion pressure
Description: : using the ultrasound Doppler technique and the tourniquet will be inflated until the arterial pulsations disappear at the side of the operation. This pressure will be recorded as LOP.using the ultrasound Doppler technique and the tourniquet will be inflated until the arterial pulsations disappear at the side of the operation. This pressure will be recorded as LOP .the tourniquet cuff will be inflated to the pressure according to theguidelines of the Association of Perioperative Registered Nurses(AORN) which recommends that a safety margin of 40 mmHg should be added for AOP below 130 mmHg, 60 mmHg for AOP between 131 mmHg and 190 mmHg, and 80 mmHg for AOP above 190 mmHg for adult patients
Study: NCT00153179

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo
Study: NCT02163525

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Global Fibroid Ablation (GFA)
Description: GFA is radiofrequency ablation of fibroids. This is a laparoscopic procedure whereby a radiofrequency probe is inserted into the fibroid under laparoscopic and ultrasound guidance. Each fibroid is heated to temperatures averaging 95 deg C. The fibroid undergoes coagulative necrosis and shrinks and/or disappears.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal or Laparoscopic Myomectomy
Description: Myomectomy is a procedure in which an incision is made into the uterus and the fibroids are surgically removed from the uterus. The uterine incision is closed with sutures. This procedure can be performed through an abdominal incision or via laparoscopy.
Study: NCT02243150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01759602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1-esterase inhibitor (Cinryze)
Study: NCT04842071

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-sodium fluoride
Description: Intravenous injection of 4 MBq/kg for pediatric patients, or 5 MBq/kg for adult patients (maximum of 555 MBq), followed by a 45 minutes waiting time. Patients is then placed in supine position in a PET/CT scanner for a duration of no more than 30 minutes.
Study: NCT01146171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-844203 (CT-322)
Description: Injection, IV, 1 and 2 mg/kg, Weekly, Until disease progression or unacceptable toxicity became apparent
Study: NCT03037593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4000 IU vitamin D3
Description: vitamin D supplementation (4000 IU vitamin D3 +prenatal vitamin
Study: NCT00127114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00443690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rolofylline
Description: rolofylline 30 mg IV QD; 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo (unspecified)
Description: rolofylline Pbo 30 mg IV QD; 3 days
Study: NCT03826056

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized discharge educational intervention
Description: The patients will receive a new personalized discharge educational material which will explain the specifics of their disorder, the treatment, and prognosis. The materials will contain simple, organized explanations and graphics. A member of the study team will explain this material to the patient and answer any questions.
Study: NCT02350465

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eccentric Exercise
Description: Submaximal progressive resistance exercise (PRE) using eccentric muscle actions for the knee extensors/flexors will be performed for 10 repetitions, 3 to 4 sets, twice per week for 12 weeks.
Study: NCT04974021

Intervention type: DRUG
Intervention: Ferric carboxymaltose
Description: Intravenous ferric carboxymaltose for the treatment of iron deficiency in HFrEF as per 2016 European Society of Cardiology Heart Failure guidelines.
Study: NCT01299324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BMAC infusion
Description: Infusion of 60 mL of Bone Marrow Aspirate Concentrate
Study: NCT02163525

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uterine Artery Embolization (UAE)
Description: UAE is a minimally invasive surgical procedure used to treat uterine fibroids. An embolic material is injected into the uterine artery(ies) to block blood flow to one or more fibroids. This procedure is performed by an interventional radiologist.
Study: NCT02052206

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shoulder replacement surgery
Study: NCT01569321

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET-CT scan

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEM scan with ClearPemSonic
Study: NCT01695681

Intervention type: OTHER
Group type: OTHER
Intervention: Gluten-free diet
Description: Dietary advice by clinical dietitian
Study: NCT03280472

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification
Description: CBM training. For those in the CBM condition, participants will complete a task. In this task, they will read ambiguous, two- to four-sentence social-related scenarios on the computer. The final word in the scenario will have a missing letter. Participants will type the missing letter. Participants will also be asked to answer a Yes/No comprehension question about the scenario. The missing letter will resolve the ambiguity of the scenario in a positive way, intended to train participants to have more positively-biased interpretations of ambiguous social information

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Symptom tracking
Description: Participants will track their symptoms
Study: NCT02726997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT02628197

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: calcium (500mg) and vitamin D (250I.U.)
Description: calcium (500mg) and vitamin D (250I.U.) was given twice a day for 6 months

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing
Description: scaling and root planing was done in the test group along with calcium (500mg) and vitamin D (250I.U.)
Study: NCT04038411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Antibody, chidamide, lenalidomide and etoposide
Description: PD-1 blocking antibody inhibits PD-1. Chidamide is an histone deacetylase inhibitor. Lenalidomide is a potent inhibitor of TNF-α. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA.
Study: NCT03405545

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intenstiy interval training
Description: High-intensity interval training is a training of 30 minutes involving 10 bouts of 1 minute high intensity cycling (80-90% of maximum heart rate) interspersed by 2 minutes rest.
Study: NCT00066573

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anastrozole
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: Given orally
Study: NCT03049592

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIBISCUS counseling
Description: Third trimester prenatal appointment with a family planning specialist for contraceptive counseling utilizing the Contraceptive CHOICE counseling script - emphasizing the WHO birth-to-pregnancy recommendation of 18 months, and a follow up postpartum contraception visit with a family planning specialist.
Study: NCT01680757

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LARIAT Suture Delivery Device and Accessories
Study: NCT04125082

Intervention type: DRUG
Group type: OTHER
Intervention: Afrezza Inhalant Product
Description: Participants will be titrated from usual pre-meal insulin plus basal to Afrezza® inhaled insulin plus basal, and will continue on treatment for 14 weeks.
Study: NCT03022526

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CSE

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine / fentaNYL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine / fentaNYL
Study: NCT01229865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VB-111
Study: NCT03785782

Intervention type: DEVICE
Intervention: Ultrasound
Description: Breast ultrasound

Intervention type: DEVICE
Intervention: Ultrasound
Description: Breast ultrasound
Study: NCT04005599

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil group
Description: Venous general anesthesia with propofol and remifentanil.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate group
Description: Venous general anesthesia with propofol and magnesium sulfate
Study: NCT03430934

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: NAVI mapping with Indocyanine green
Description: Moh's tumor imaging with Indocyanine green
Study: NCT04459377

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-Ketamine
Description: Patients are randomized to three groups. Randomization in blocks of six patients stratified by sex. A list of serial numbers and randomized group affiliation is produced which is open to the pharmacy's manufacturing staff and closed to the staff of the trial. The pharmacy prepares filled syringes with investigation drug in accordance with randomized group affiliation.~All groups are sedated with midazolam intravenously to a defined end point. A syringe pump with volume accuracy ± 2% injects the test drug (P, K1 or K2). One infusion set is coupled between the syringe and a three-way connection, which in turn is connected to a peripheral venous catheter (PVK). This PVK is also used for blood sampling. Blood is sampled at two occasions. Directly preoperatively and two hours after surgery. The third molar is surgically removed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-Ketamine
Description: Patients are randomized to three groups. Randomization in blocks of six patients stratified by sex. A list of serial numbers and randomized group affiliation is produced which is open to the pharmacy's manufacturing staff and closed to the staff of the trial. The pharmacy prepares filled syringes with investigation drug in accordance with randomized group affiliation.~All groups are sedated with midazolam intravenously to a defined end point. A syringe pump with volume accuracy ± 2% injects the test drug (P, K1 or K2). One infusion set is coupled between the syringe and a three-way connection, which in turn is connected to a peripheral venous catheter (PVK). This PVK is also used for blood sampling. Blood is sampled at two occasions. Directly preoperatively and two hours after surgery. The third molar is surgically removed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9% Inj
Description: Patients are randomized to three groups. Randomization in blocks of six patients stratified by sex. A list of serial numbers and randomized group affiliation is produced which is open to the pharmacy's manufacturing staff and closed to the staff of the trial. The pharmacy prepares filled syringes with investigation drug in accordance with randomized group affiliation.~All groups are sedated with midazolam intravenously to a defined end point. A syringe pump with volume accuracy ± 2% injects the test drug (P, K1 or K2). One infusion set is coupled between the syringe and a three-way connection, which in turn is connected to a peripheral venous catheter (PVK). This PVK is also used for blood sampling. Blood is sampled at two occasions. Directly preoperatively and two hours after surgery. The third molar is surgically removed.
Study: NCT02246907

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: All intervention patients will participate in an individualized prescriptive exercise intervention 2 to 4 times per week for a period of the induction chemotherapy/in-hospital recovery. The exercise intervention will begin on week 1 of the study, the day after the first batteries of initial assessments are concluded. Each exercise session will be divided into two parts. One part will be administered in the morning and the second one late in the afternoon. There will be a period of rest of at least 36 hours between each exercise session.
Study: NCT03987516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active exercising
Description: Patients allocated to the experimental group were included in an active exercising program adapted to each patient
Study: NCT04391114

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional HoLEP
Description: Holmium laser enucleation of the prostate (HoLEP), first reported by Fraundorfer et al in 1998, is a more recent step in the evolution of holmium laser prostatectomy. HoLEP is a safe and effective procedure which has demonstrated comparable results to TURP and open prostatectomy for patients with symptomatic enlarged prostate, with low morbidity and short hospital stay \[4\]. The improvement in outcome parameters is durable, and the late complications and reoperation rates reported are very low \[5\]. HoLEP is equally suitable for small, medium and larger prostate glands, with clinical outcomes that are independent of prostate size, unlike TURP. HOLEP offers patients the alterative of being treated endoscopically with minimal blood loss, short catheterization time, and decreased hospital stay \[6\].

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Top-Down HoLEP
Description: The main difference between the Top-Down and Traditional approach is that the direction of lateral dissection begins from upwards to downwards. This could help in avoiding the overtraction of the mucosal strip overlying the posterior urethral sphincter, which theoretically leads to a decrease in the incidence of postoperative stress incontinence. Moreover, using the Top-Down approach should lead to a decrease in the incidence of lost enucleation planes, which results in decreasing the intraoperative time and decreasing the number of cases required to master the HoLEP technique.
Study: NCT02618902

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tolerogenic dendritic cells (tolDC)
Description: dose-escalation
Study: NCT02347306

Intervention type: OTHER
Intervention: Telephone interview
Study: NCT02243150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT04488029

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PCT
Description: PCT is designed to deliver similar therapy as is conventionally provided in-clinic by a Speech Language Pathologist (SLP), which the patient can access from any location using the application installed on a supported tablet. The device functions by allowing clinicians to create a personalized therapy program for each patient from 75 categories of clinical therapies, which patients may access from their tablet device remotely. The PCT software is comprised primarily of authentication and an algorithm that suggests advancement of the therapy program based on observed patient deficits and progress.
Study: NCT03037138

Intervention type: OTHER
Group type: OTHER
Intervention: Blood flow Rate profiling
Description: Blood flow rate profiling during dialysis session
Study: NCT01946152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim-sndz
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given PO
Study: NCT04692519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Duet Language Intervention Modules
Description: The Duet 2.0 intervention modules promote the following guiding principles that help build effective communication. Below are the 5 principles covered in the six Duet modules: 1) General Awareness: Awareness and knowledge of child development 2) Creating Opportunities: Opportunities for communication during everyday activities 3) Conversational Duets: Rhythmic and reciprocal early language interactions 4) Scaffolding: Providing just enough help to support child independence 5) Harmonizing: Using the strategies together. These modules, which include behavioral strategies, real-life and animated examples of high-quality early language interactions, and interactive scenarios. The modules were informed and narrated by community members and carefully designed to address specific needs of high-risk communities. The modules have also been translated into Spanish, making sure to encompass specific cultural and dialect needs. Translation accuracy was verified by a qualified Spanish translator.
Study: NCT00994006

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium oxide
Description: 520 mg of elemental magnesium q.d.
Study: NCT01487109

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTP-499
Description: 600 mg tablet twice daily
Study: NCT00994006

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium citrate
Description: Magnesium citrate , 98.6 mg of elemental magnesium t.i.d.